MedPath

Effects of Almond Versus Pistachio on Weight Loss

Not Applicable
Completed
Conditions
Obesity
Overweight
Interventions
Behavioral: Almond Group
Behavioral: Nut free group
Behavioral: Pistachio Group
Registration Number
NCT03120455
Lead Sponsor
Novindiet Clinic
Brief Summary

The purpose of the current study is comparing the effect of almond and pistachio, as the two common types of nuts, consumption on healthy obese and overweight female who following a hypocaloric diet for 12 weeks. The secondary aim of the current study is to evaluate of these two type of nuts on other cardiometabolic risk factors.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
120
Inclusion Criteria
  • Must be female
  • Must be 18-45 years of age.
  • Must have Body mass index (BMI) between 27-35 kg/ m².
  • Must be able to have moderate exercise.
  • Must be interested to have weight loss.
Exclusion Criteria
  • Have allergy to nuts
  • Participating in a research project involving weight loss or physical activity in the previous six months.
  • Pregnancy or lactation during the previous 6 months, or planned pregnancy in the next six months.
  • Taking medication that could affect metabolism or change body weight.
  • Report heart problems, chest pain, and cancer within the last five years.
  • Smoking
  • Menopause
  • Diagnosis of any chronic disease such as fatty liver, cancer, chemo/radio therapy, heart disease, immune compromised conditions, abnormal thyroid hormone level.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Almond group (AG)Almond GroupObese or overweight female adults will be randomly allocated to have have almond as afternoon snack while they have a hypoenergetic diet.
Nut Free (NFG, CG)Nut free groupObese or overweight female adults are asked to avoid all nuts, seeds, and nut products while they have a hypoenergetic diet. , as the control group.
Pistachio group (PG)Pistachio GroupObese or overweight female adults will be randomly allocated to have have Pistachio as afternoon snack while they have a hypoenergetic diet.
Primary Outcome Measures
NameTimeMethod
Weight12 Weeks

Body weight was taken to the nearest 0.1 kg using a digital calibrated scale (Omron Health Care, Hoofddorp, Netherland), whilst subjects wore light clothing and no shoes.

Secondary Outcome Measures
NameTimeMethod
Waist circumference12 Weeks

Waist circumference (WC) was measured with a rigid measuring tape and recorded to the nearest 0.5 cm. WC was measured at the smallest horizontal circumference between the ribs and iliac crest (the natural waist), or, in case of an indeterminable waist narrowing, halfway between the lower rib and the iliac crest.

HbA1c12 Weeks

Glycated hamoglobin (HbA1c) was measured by a colorimetric method after an initial separation by ion exchange chromatography (Biosystem, Barcelona, Spain).

lipid profiles12 Weeks

Biochemical analysis of the serum total cholesterol (TC), triglyceride (TG), and high-density lipoprotein (HDL) cholesterol was carried out on a Selectra E auto analyzer (Vita Laboratory, Netherlands) following standard procedures of the Pars Azmoon diagnostic kits (Iran). The LDL cholesterol was calculated using the Friedewald formula.

LDL cholesterol = TC - HDL cholesterol + (TG ÷ 2.2)

fasting blood glucose12 Weeks

Fasting plasma glucose (FPG) were measured using the enzymatic colorimetric method.

HOMA-IR12 Weeks

Insulin resistance was evaluated by homeostasis model assessment of insulin resistance (HOMA-IR), which was calculated by using the following formula HOMA-IR = \[fasting insulin (mU/l) × FPG (mmol/l)\]/22.5

liver function tests12 Weeks

AST ALT

Insulin12 Weeks

Insulin was measured by using a radioimmunoassay with 125I-labeled human insulin and a human insulin antiserum in an immunoradiometric assay (IRMA) (Biosource, Dorest, Belgium) with a gamma-counter system (Gamma I; Genesys).

Trial Locations

Locations (1)

NovinDiet Clinic

🇮🇷

Tehran, Iran, Islamic Republic of

© Copyright 2025. All Rights Reserved by MedPath